ALBENDAZOLE

Search structure


Trade Names:	ALBENDAZOLE ALBENZA
Synonyms:	Albendazole Albendazolum Albenza Andazol Eskazole NSC-220008 SK&F 62979 SK&F-62979 Valbazen Zental Zentel
Status:	Approved (1996)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	P02CA03
UNII:	F4216019LN

Structure


InChI Key	HXHWSAZORRCQMX-UHFFFAOYSA-N
Smile	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
InChI	InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C12H15N3O2S
Molecular Weight	265.34
AlogP	3.24
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	4.0
Polar Surface Area	67.01
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	18.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Tubulin inhibitor	ISBN PubMed DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Protease Metallo protease Metallo protease MG clan Metallo protease M24A subfamily	-	-	-	-	10
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	103

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Helminthiasis	4	D006373	ClinicalTrials
Elephantiasis, Filarial	3	D004605	ClinicalTrials
HIV Infections	3	D015658	ClinicalTrials
Cysticercosis	3	D003551	ClinicalTrials
Onchocerciasis	3	D009855	ClinicalTrials
Strongyloidiasis	3	D013322	ClinicalTrials
Toxocariasis	3	D014120	ClinicalTrials
Malaria	3	D008288	ClinicalTrials
Malnutrition	3	D044342	ClinicalTrials
Filariasis	3	D005368	ClinicalTrials
Ectoparasitic Infestations	3	D004478	ClinicalTrials
Hookworm Infections	2	D006725	ClinicalTrials
Trichuriasis	2	D014257	ClinicalTrials

Related Entries

MCS

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend :

Indication

Mechanism of Action

Primary Target

Target Level

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Investigations Liver function test abnormal	15.6
Nervous system disorders Headache	11.0
Gastrointestinal disorders Nausea	6.2
Gastrointestinal disorders Vomiting	6.2
Gastrointestinal disorders Abdominal pain	6.0
Gastrointestinal disorders Gastrointestinal pain	6.0
Gastrointestinal disorders Nausea	3.7
Gastrointestinal disorders Vomiting	3.7
Skin and subcutaneous tissue disorders Alopecia	1.6
Nervous system disorders Intracranial pressure increased	1.5
Nervous system disorders Headache	1.3
Cardiac disorders Dizziness	1.2
Ear and labyrinth disorders Vertigo	1.2
Skin and subcutaneous tissue disorders Alopecia	1.0
Investigations Body temperature increased	1.0
Cardiac disorders Dizziness	1.0
Investigations Liver function test abnormal	1.0
Ear and labyrinth disorders Vertigo	1.0
Blood and lymphatic system disorders Leukopenia	0.7

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	16.77
Injury, poisoning and procedural complications	11.68
Gastrointestinal disorders	10.12
Nervous system disorders	9.84
Skin and subcutaneous tissue disorders	6.18
Infections and infestations	5.63
Vascular disorders	4.62
Pregnancy, puerperium and perinatal conditions	3.6
Respiratory, thoracic and mediastinal disorders	3.6
Eye disorders	3.33
Blood and lymphatic system disorders	3.12
Cardiac disorders	3.12
Investigations	2.92
Psychiatric disorders	2.72
Immune system disorders	2.17
Hepatobiliary disorders	2.1

Cross References

Resources	Reference
CAS NUMBER	54965-21-8
ChEBI	16664
ChEMBL	CHEMBL1483
DrugBank	DB00518
DrugCentral	103
EPA CompTox	DTXSID0022563
FDA SRS	F4216019LN
Human Metabolome Database	HMDB0014659
KEGG	C01779
PharmGKB	PA164746058
PubChem	2082
SureChEMBL	SCHEMBL44682
ZINC	ZINC000017146904

CONTENTS